<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03875157</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI318A101</org_study_id>
    <nct_id>NCT03875157</nct_id>
  </id_info>
  <brief_title>Study of IBI318 in Participants With Advanced Malignancies</brief_title>
  <official_title>To Evaluate the Safety, Tolerability, and Initial Efficacy of IBI318 in Patients With Advanced Malignancy, Multicenter, IA/IB Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open, multicenter, Ia/Ib phase study to evaluate the safety, tolerability,
      and initial efficacy of IBI318 in the treatment of patients with advanced malignancy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 19, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants experiencing dose-limiting toxicities (DLTs)</measure>
    <time_frame>28 days within first dose in phase Ia</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants experiencing clinical and laboratory adverse events (AEs)</measure>
    <time_frame>Up to 90 days post last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of all study participants who demonstrate a tumor response</measure>
    <time_frame>up to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The area under the curve (AUC) of plasma concentration of drug against time after administration of IBI318</measure>
    <time_frame>Up to 90 days post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) after first dose interval of IBI318</measure>
    <time_frame>Up to 90 days post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time at which maximum concentration (Tmax) occurs for IBI318</measure>
    <time_frame>Up to 90 days post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The half-life (t1/2) of IBI318 in plasma</measure>
    <time_frame>Up to 90 days post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive rate of ADA and Nab</measure>
    <time_frame>Up to 90 days post last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Anticipated">327</enrollment>
  <condition>Advanced Malignancy</condition>
  <arm_group>
    <arm_group_label>IBI318 DL1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IBI318 DL2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IBI318 DL3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IBI318 DL4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IBI318 DL5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IBI318 DL6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IBI318 DL7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IBI318 DL8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IBI318 DL7b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IBI318 DL8b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IBI318 RP2D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IBI318</intervention_name>
    <description>0.3mg Intravenous infusion, first day of first cycle and afterwards Q2W</description>
    <arm_group_label>IBI318 DL1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IBI318</intervention_name>
    <description>1mg Intravenous infusion, first day of first cycle and afterwards Q2W</description>
    <arm_group_label>IBI318 DL2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IBI318</intervention_name>
    <description>3mg Intravenous infusion, first day of first cycle and afterwards Q2W</description>
    <arm_group_label>IBI318 DL3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IBI318</intervention_name>
    <description>10mg Intravenous infusion, first day of first cycle and afterwards Q2W</description>
    <arm_group_label>IBI318 DL4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IBI318</intervention_name>
    <description>30mg Intravenous infusion, first day of first cycle and afterwards Q2W</description>
    <arm_group_label>IBI318 DL5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IBI318</intervention_name>
    <description>100mg Intravenous infusion, first day of first cycle and afterwards Q2W</description>
    <arm_group_label>IBI318 DL6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IBI318</intervention_name>
    <description>300mg Intravenous infusion, first day of first cycle and afterwards Q2W</description>
    <arm_group_label>IBI318 DL7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IBI318</intervention_name>
    <description>600mg Intravenous infusion, first day of first cycle and afterwards Q2W</description>
    <arm_group_label>IBI318 DL8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IBI318</intervention_name>
    <description>Intravenous infusion, first day of first cycle and afterwards Q3W</description>
    <arm_group_label>IBI318 DL7b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IBI318</intervention_name>
    <description>Intravenous infusion, first day of first cycle and afterwards Q3W</description>
    <arm_group_label>IBI318 DL8b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IBI318</intervention_name>
    <description>Intravenous infusion Q3W</description>
    <arm_group_label>IBI318 RP2D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Sign the written informed consent form;

          2. Men or women aged 18 years or older;

          3. Expected survival time â‰¥ 12 weeks;

          4. Tumor assessment according to RECIST v1.1, at least one measurable lesion.

          5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;

          6. Have adequate organ and bone marrow function;

          7. Male participants and female participants must agree to use contraception during the
             treatment period and within 180 days after the treatment period;

          8. Female subjects must not be pregnant, not breastfeeding: have evidence of
             postmenopausal status, or urine or serum pregnancy tests are negative in premenopausal
             status.

          9. Ia: Subjects with locally advanced, recurrent or metastatic histologically or
             cytologically confirmed solid tumors or hematologic tumors and refractory or tolerant
             to existing standard treatments.

         10. Ib: Metastatic non-small cell lung cancer, advanced liver cancer, advanced esophageal
             squamous cell cancer, advanced gastric cancer and other tumors that have been proved
             by histology or cytology with initial therapeutic effect in Phase Ia

        Exclusion Criteria:

          1. Previously exposed to immune-therapies including, but not limited to, anti-CTLA-4,
             anti-PD-1, anti-PD-L1, and anti-PD-L2 antibodies, excluding therapeutic anti-tumor
             vaccine;

          2. Participating in another interventional clinical study, or an observational
             (non-interventional) clinical study or a follow-up phase of an interventional study;

          3. Receive the last anti-tumor treatment within 4 weeks prior to the first dose of study
             drug;

          4. Use of immunosuppressive drugs within 4 weeks prior to the first dose of study drug;

          5. Require long-term steroid therapy or any other form of immunosuppressive therapy not
             including inhaled steroids;

          6. In 4 weeks prior to the first dose of study drug, there was toxicity (excluding hair
             loss or fatigue) caused by previous antitumor therapy that did not recover to NCI
             CTCAE v5.0 level 0-1 or level as the inclusion criteria;

          7. Received major surgery or has unhealed wounds, ulcers or fractures within 4 weeks
             prior to the first dose of study drug;

          8. Expect to receive other anti-tumor treatments during study (allowing palliative
             radiotherapy);

          9. History of infectious) pneumonitis that required steroids or has current pneumonitis;

         10. Known active untreated CNS metastases and/or spinal cord compression and/or cancerous
             meningitis, or with a history of soft meningeal cancer;

         11. Active autoimmune disease that has required systemic treatment in past 2 yearsï¼›

         12. Known active Hepatitis B or Hepatitis C virus;

         13. Uncontrolled concomitant diseases or neurological, psychiatric/social conditions that
             affect the compliance to the study, significantly increase the risk of adverse events,
             or affect the subject's ability to provide written informed consent;

         14. Known history of human immunodeficiency virus (HIV) infection;

         15. Known history of active tuberculosis (TB; Bacillus tuberculosis) or active syphilis;

         16. History of allogeneic organ transplantation and hematopoietic stem cell
             transplantation;

         17. Accompanied by uncontrolled third interstitial fluids requiring repeated drainage,
             such as pleural effusion, ascites, pericardial effusion, etc.

         18. Known severe allergic reactions to other monoclonal antibodies or are allergic to any
             IBI318 formulation component;

         19. Female subjects during pregnancy or lactation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>jinjin chen</last_name>
    <phone>86-512-69566088</phone>
    <email>jinjin.chen@innoventbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruihua Xu, M.D.,Ph.D</last_name>
      <phone>86-20-87343466</phone>
      <email>xurh@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 28, 2019</study_first_submitted>
  <study_first_submitted_qc>March 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2019</study_first_posted>
  <last_update_submitted>April 23, 2019</last_update_submitted>
  <last_update_submitted_qc>April 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

